114 related articles for article (PubMed ID: 24333842)
1. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
Conner JR; Meserve E; Pizer E; Garber J; Roh M; Urban N; Drescher C; Quade BJ; Muto M; Howitt BE; Pearlman MD; Berkowitz RS; Horowitz N; Crum CP; Feltmate C
Gynecol Oncol; 2014 Feb; 132(2):280-6. PubMed ID: 24333842
[TBL] [Abstract][Full Text] [Related]
2. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA
J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
[TBL] [Abstract][Full Text] [Related]
4. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Chen LM; Richardson DL;
Gynecol Oncol; 2015 Jan; 136(1):3-7. PubMed ID: 25238946
[TBL] [Abstract][Full Text] [Related]
5. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Robson ME; Bradbury AR; Arun B; Domchek SM; Ford JM; Hampel HL; Lipkin SM; Syngal S; Wollins DS; Lindor NM
J Clin Oncol; 2015 Nov; 33(31):3660-7. PubMed ID: 26324357
[TBL] [Abstract][Full Text] [Related]
7. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
8. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
9. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
Zakhour M; Danovitch Y; Lester J; Rimel BJ; Walsh CS; Li AJ; Karlan BY; Cass I
Gynecol Oncol; 2016 Nov; 143(2):231-235. PubMed ID: 27623252
[TBL] [Abstract][Full Text] [Related]
10. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Kotsopoulos J; Huzarski T; Gronwald J; Singer CF; Moller P; Lynch HT; Armel S; Karlan B; Foulkes WD; Neuhausen SL; Senter L; Tung N; Weitzel JN; Eisen A; Metcalfe K; Eng C; Pal T; Evans G; Sun P; Lubinski J; Narod SA;
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27601060
[TBL] [Abstract][Full Text] [Related]
11. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
Curtis KM; Tepper NK; Jatlaoui TC; Berry-Bibee E; Horton LG; Zapata LB; Simmons KB; Pagano HP; Jamieson DJ; Whiteman MK
MMWR Recomm Rep; 2016 Jul; 65(3):1-103. PubMed ID: 27467196
[TBL] [Abstract][Full Text] [Related]
12. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
[TBL] [Abstract][Full Text] [Related]
13. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
14. Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review.
Dumont A; Robin G; Catteau-Jonard S; Dewailly D
Reprod Biol Endocrinol; 2015 Dec; 13():137. PubMed ID: 26691645
[TBL] [Abstract][Full Text] [Related]
15. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents.
Inge TH; Courcoulas AP; Jenkins TM; Michalsky MP; Helmrath MA; Brandt ML; Harmon CM; Zeller MH; Chen MK; Xanthakos SA; Horlick M; Buncher CR;
N Engl J Med; 2016 Jan; 374(2):113-23. PubMed ID: 26544725
[TBL] [Abstract][Full Text] [Related]
16. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults.
Skinner AC; Perrin EM; Moss LA; Skelton JA
N Engl J Med; 2015 Oct; 373(14):1307-17. PubMed ID: 26422721
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer risk after salpingectomy: a nationwide population-based study.
Falconer H; Yin L; Grönberg H; Altman D
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25628372
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
